CY1112190T1 - Θεραπεια της εξαρτωμενης απο το μηκος νευροπαθειας - Google Patents
Θεραπεια της εξαρτωμενης απο το μηκος νευροπαθειαςInfo
- Publication number
- CY1112190T1 CY1112190T1 CY20111100291T CY111100291T CY1112190T1 CY 1112190 T1 CY1112190 T1 CY 1112190T1 CY 20111100291 T CY20111100291 T CY 20111100291T CY 111100291 T CY111100291 T CY 111100291T CY 1112190 T1 CY1112190 T1 CY 1112190T1
- Authority
- CY
- Cyprus
- Prior art keywords
- painful
- neuropathy
- treatment
- patients
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Παρέχονται συνθέσεις και μέθοδοι χρήσης αυτών, για τη θεραπεία επώδυνης νευροπάθειας με τοπική χορήγηση ενώσεων που αλληλεπιδρούν με α-αδρενεργικούς υποδοχείς, ιδιαίτερα έναν άλφα2 αδρενεργικό ανταγωνιστή όπως είναι η κλονιδίνη, σε ολόκληρη την επώδυνη περιοχή, ώστε η ανάγκη για συστηματική δόση να μειώνεται στο ελάχιστο. Οι ενώσεις χορηγούνται στις ή κοντά στις επώδυνες περιοχές σε ασθενείς με επώδυνη, εξαρτώμενη από το μήκος νευροπάθεια, καθώς και με άλλες νευροπάθειες που επηρεάζουν τις ίνες του δέρματος που σηματοδοτούν πόνο. Μία προτιμώμενη ένωση για τη θεραπεία ασθενών με νευροπάθεια εξαρτώμενη από το μήκος, είναι η κλονιδίνη, εφαρμοσμένη σε μορφή ενός διαδερμικού έμπλαστρου, γέλης, αλοιφής, λοσιόν, λιποσωμικής σύνθεσης, κρέμας ή γαλακτώματος, όπου η συγκέντρωση είναι αρκετή για να παρέχει μια αποτελεσματική δόση στην επώδυνη περιοχή ή τις άμεσα γειτνιάζουσες περιοχές.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73442305P | 2005-11-08 | 2005-11-08 | |
EP06837161A EP1962836B1 (en) | 2005-11-08 | 2006-11-07 | Treatment of length dependent neuropathy |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112190T1 true CY1112190T1 (el) | 2015-12-09 |
Family
ID=37946498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100291T CY1112190T1 (el) | 2005-11-08 | 2011-03-15 | Θεραπεια της εξαρτωμενης απο το μηκος νευροπαθειας |
Country Status (16)
Country | Link |
---|---|
EP (2) | EP1962836B1 (el) |
JP (2) | JP5044566B2 (el) |
KR (1) | KR101389184B1 (el) |
CN (2) | CN101365445A (el) |
AT (1) | ATE493128T1 (el) |
AU (2) | AU2006311580B2 (el) |
CA (1) | CA2628794C (el) |
CY (1) | CY1112190T1 (el) |
DE (1) | DE602006019311D1 (el) |
DK (1) | DK1962836T3 (el) |
ES (1) | ES2357033T3 (el) |
HK (1) | HK1123501A1 (el) |
PL (1) | PL1962836T3 (el) |
PT (1) | PT1962836E (el) |
SI (1) | SI1962836T1 (el) |
WO (1) | WO2007056460A2 (el) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012012333A1 (en) * | 2010-07-19 | 2012-01-26 | Arcion Therapeutics, Inc. | Topical treatment of neuropathic pain and methods of diagnosis |
CN101947222A (zh) * | 2010-08-18 | 2011-01-19 | 徐震 | 一种用于治疗高血压的软膏剂及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447947A (en) | 1990-02-26 | 1995-09-05 | Arc 1 | Compositions and methods of treatment of sympathetically maintained pain |
CA2104873C (en) * | 1991-02-26 | 2000-05-23 | James N. Campbell | Compositions and methods of treatment of sympathetically maintained pain |
PT901790E (pt) * | 1997-09-16 | 2001-09-28 | Solvay Pharm Gmbh | Utilizacao de moxonidina para o tratamento de dor neuropatica |
US6147102A (en) | 1999-10-26 | 2000-11-14 | Curatek Pharmaceuticals Holding, Inc. | Clonidine preparations |
US7687080B2 (en) * | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
US20090325975A1 (en) * | 2005-07-15 | 2009-12-31 | Helmut H Buschmann | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
-
2006
- 2006-11-07 CN CNA2006800479611A patent/CN101365445A/zh active Pending
- 2006-11-07 ES ES06837161T patent/ES2357033T3/es active Active
- 2006-11-07 DE DE602006019311T patent/DE602006019311D1/de active Active
- 2006-11-07 PL PL06837161T patent/PL1962836T3/pl unknown
- 2006-11-07 AT AT06837161T patent/ATE493128T1/de active
- 2006-11-07 WO PCT/US2006/043499 patent/WO2007056460A2/en active Application Filing
- 2006-11-07 KR KR1020087011106A patent/KR101389184B1/ko not_active IP Right Cessation
- 2006-11-07 DK DK06837161.6T patent/DK1962836T3/da active
- 2006-11-07 CN CN201510491599.8A patent/CN105147674A/zh active Pending
- 2006-11-07 EP EP06837161A patent/EP1962836B1/en not_active Not-in-force
- 2006-11-07 PT PT06837161T patent/PT1962836E/pt unknown
- 2006-11-07 EP EP10173217A patent/EP2343068A3/en not_active Ceased
- 2006-11-07 JP JP2008540162A patent/JP5044566B2/ja not_active Expired - Fee Related
- 2006-11-07 CA CA2628794A patent/CA2628794C/en not_active Expired - Fee Related
- 2006-11-07 AU AU2006311580A patent/AU2006311580B2/en not_active Ceased
- 2006-11-07 SI SI200630943T patent/SI1962836T1/sl unknown
-
2009
- 2009-02-13 HK HK09101396.9A patent/HK1123501A1/xx not_active IP Right Cessation
-
2010
- 2010-08-25 AU AU2010214659A patent/AU2010214659B2/en not_active Ceased
-
2011
- 2011-03-15 CY CY20111100291T patent/CY1112190T1/el unknown
-
2012
- 2012-02-15 JP JP2012030574A patent/JP2012097121A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN101365445A (zh) | 2009-02-11 |
HK1123501A1 (en) | 2009-06-19 |
KR101389184B1 (ko) | 2014-04-24 |
SI1962836T1 (sl) | 2011-04-29 |
AU2006311580A1 (en) | 2007-05-18 |
ATE493128T1 (de) | 2011-01-15 |
AU2006311580B2 (en) | 2010-06-24 |
ES2357033T3 (es) | 2011-04-15 |
CA2628794C (en) | 2012-01-03 |
JP2012097121A (ja) | 2012-05-24 |
CN105147674A (zh) | 2015-12-16 |
CA2628794A1 (en) | 2007-05-18 |
WO2007056460A2 (en) | 2007-05-18 |
EP2343068A2 (en) | 2011-07-13 |
KR20080091756A (ko) | 2008-10-14 |
PT1962836E (pt) | 2011-03-01 |
JP5044566B2 (ja) | 2012-10-10 |
WO2007056460A3 (en) | 2007-08-23 |
EP1962836B1 (en) | 2010-12-29 |
AU2010214659A1 (en) | 2010-09-16 |
EP1962836A2 (en) | 2008-09-03 |
AU2010214659B2 (en) | 2012-02-02 |
PL1962836T3 (pl) | 2011-06-30 |
DK1962836T3 (da) | 2011-02-28 |
EP2343068A3 (en) | 2012-06-13 |
DE602006019311D1 (de) | 2011-02-10 |
JP2009514970A (ja) | 2009-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6921529B2 (en) | Treatment modality and method for fungal nail infection | |
Alley et al. | Cutaneous toxicities of cancer therapy | |
US5750141A (en) | Administration of vaso-active agent and therapeutic agent | |
JP4931128B2 (ja) | Trpv1アゴニストの投与のための方法および組成物 | |
US6676953B2 (en) | Antifungal composition and method for human nails | |
EA200301200A1 (ru) | Проникающая через кожу композиция селективного ингибитора циклооксигеназы-2 | |
BRPI0410169A (pt) | dispositivo manual para aplicação de um material de barreira a uma mecha de cabelos; e método para aplicação de um material de barreira a uma mecha de cabelos a ser tratada | |
EA200601777A1 (ru) | Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии | |
JP2001354591A (ja) | 爪甲真菌症処置の方法 | |
US20090215888A1 (en) | Topical nail formulation | |
ES2782774T3 (es) | Composiciones que comprenden benzofuroquinolizina y agonistas alfa2-adrenérgicos sustituidos | |
HUE034680T2 (en) | Transdermal pharmaceutical compositions containing SERM | |
JP2014518239A (ja) | 皮膚反応を低減するための新規な安定麻酔組成物 | |
RU2006133386A (ru) | Композиции по уходу за кожей, содержащие салициловую кислоту | |
CY1112190T1 (el) | Θεραπεια της εξαρτωμενης απο το μηκος νευροπαθειας | |
JP2006527234A5 (el) | ||
WO2006113796A3 (en) | Microbial cellulose materials for use in transdermal drug delivery system | |
CA2495923A1 (en) | Methods for treating fungal infections | |
AR045178A1 (es) | Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composicion farmaceutica | |
BR0014751A (pt) | Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto | |
BRPI0414112A (pt) | uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono | |
CO5011042A1 (es) | Uso de una oxazolidinona para la fabricacion de un medicamento para administracion topica | |
JP6016085B2 (ja) | 抗真菌外用組成物及び抗真菌外用組成物の適用方法 | |
BRPI0513002A (pt) | composição para administração tópica ou transdérmica, e, métodos para tratar fragilidades das unhas, unhas espessas, crescimento anormal de unhas, e secura de pele em um paciente, para aumentar a penetração de um agente bioativo através da unha de um humano ou animal de sangue quente, para suprir um agente bioativo transdermicamente, e para produzir uma composição para suprimento transdérmico de um agente bioativo | |
Ghosh et al. | Studies of Ringworm. Part III. Prophylactic Measures |